TICKERNERD
Menu
JSPRJSPRHealthcare · Biotechnology

JSPR Stock Forecast: Jasper Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 28 Oct 2026
$0.54
+3.82% on the day

The 2 Wall Street analysts covering Jasper Therapeutics, Inc. hold a median 12-month price target of $20 — +3612.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 42 of 100 as at 27 Oct 2026 — in the lower half.

Market cap
$17.9M
Ticker Nerd rank
42/ 100
Median analyst target
$20
Analysts covering
2
Revenue$0.0
Operating income−$9.2M
Net income−$2.8M
Free cash flow−$6.9M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+6.9%
1M
−13.9%
YTD
−70.6%
1Y
−77.0%
From 52W high
−77.2%
From 52W low
+58.0%
$0.34
$2.36
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

JSPR stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Jasper Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 27 Oct 2026
42/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
88
Growth
87
Revisions
71
Issuance
63
Accruals
42
Momentum
24
Value
13
Volatility
12
Quality
11

Size (88): Smaller than most of the companies we track.

Quality (11): Profits are thin or unreliable for the size of the business, or they are not turning into cash.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

JSPR stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on JSPR, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$5.00$10.00$15.00$20.00Jan 26Apr 26Jul 26Oct 26JSPRHigh $20Median $20Low $20

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says2 analysts
2 Buy0 Hold0 Sell
Low $20Median $20High $20

The green dot is the last close — the median target sits +3612.0% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
14 Oct 2026William BlairReinstatesOutperform—
12 Aug 2026Piper SandlerInitiatesOverweight$2.00
12 Aug 2026Piper SandlerInitiatesOverweight—
15 May 2026RBC CapitalMaintainsSector Perform—
15 May 2026RBC CapitalMaintainsSector Perform$4.00 → $3.00
15 May 2026TD CowenDowngradeHold—
15 May 2026TD CowenDowngradeHold—
1 Apr 2026Evercore ISI GroupMaintainsOutperform—
23 Mar 2026UBSAssumesNeutral$1.50
11 Nov 2025RBC CapitalMaintainsSector Perform—
22 Sept 2025BTIGMaintainsBuy—
22 Sept 2025Evercore ISI GroupMaintainsOutperform—
22 Sept 2025JMP SecuritiesMaintainsMarket Outperform—
15 Aug 2025UBSMaintainsBuy—
8 July 2025BMO CapitalDowngradeMarket Perform—
8 July 2025Evercore ISI GroupMaintainsOutperform—
8 July 2025JMP SecuritiesMaintainsMarket Outperform—
7 July 2025BTIGMaintainsBuy—
7 July 2025Cantor FitzgeraldDowngradeNeutral—
7 July 2025HC Wainwright & Co.MaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

JSPR appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.

Free. Unsubscribe any time.

The AI build-out map
PDF

  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and serversIn full

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

JSPR vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 28 Oct 2026, Jasper Therapeutics, Inc. returned −77.0% against +13.6% for the S&P 500, dividends included.

JSPR vs S&P 500, last 12 monthsTotal return, rebased to 100
020406080100120Jan 26Apr 26Jul 26Oct 26JSPRS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

JSPR analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
0
Fundamentals

Jasper Therapeutics, Inc. (JSPR) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−0.1×

Cheaper than 78% of US stocks

Price / sales
—
Price / book
10.8×

Cheaper than 9% of US stocks

EV / EBITDA
0.1×

Cheaper than 61% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−1826.1%

Higher than 1% of US stocks

Return on assets
−211.9%

Higher than 1% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Jasper Therapeutics, Inc. (JSPR) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Jasper Therapeutics, Inc. has a market value of $17.9M and an enterprise value of −$9.5M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$31.8M.

  • Diluted earnings per share, trailing twelve months: $−1.59.

  • Free cash flow in the twelve months to 30 June 2026: −$60.3M.

  • Shares outstanding: 28.1M.

  • Trailing P/E: −0.1×; forward P/E: −0.8× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Jasper Therapeutics, Inc. employs 22 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 29 Oct 2026

Data provided by Twelve Data

Peers

JSPR vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
JSPRJasper Therapeutics, Inc.$17.9M42
MCRBSeres Therapeutics, Inc.$17.3M55
KYNBKyntra Bio, Inc.$18.2M43
NEUPNeuphoria Therapeutics, Inc.$18.2M8
QNTMQuantum BioPharma Ltd.$18.8M47
MRKRMarker Therapeutics, Inc.$15.9M64
COCPCocrystal Pharma, Inc.$18.9M58

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Jasper Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest JSPR news & analysis

Jasper Therapeutics Announces Completion of Enrollment in First Cohort of Phase 2 Renal Basket Study Evaluating Vensobafusp Alfa (KP104) in IgA Nephropathy

GlobeNewsWire · 15 Oct 2026positive

Jasper Therapeutics announced completion of enrollment in the IgA nephropathy cohort of its Phase 2 renal basket study evaluating vensobafusp alfa (KP104). Initial Stage 1 data are expected by year-end 2026, and the company announced an FSGS expansion cohort, with first dosing anticipated in the first quarter of 2027.

Why it matters — The enrollment milestone and planned expansion mark progress in Jasper’s clinical evaluation of KP104 for kidney diseases.

Jasper Therapeutics Announces Commencement of an Offer to Purchase Outstanding Warrants

GlobeNewsWire · 7 Oct 2026neutral

Jasper Therapeutics has commenced an offer to purchase any and all outstanding warrants issued in its September 18, 2025 public offering for $0.324 in cash per warrant, without interest. Warrants tendered will be retired and cancelled.

Why it matters — The company says the offer is intended to reduce potential share dilution from warrant exercises and provide greater certainty about its capital structure.

Jasper Therapeutics Announces Key Regulatory and Clinical Appointments

GlobeNewsWire · 15 Sept 2026neutral

Jasper Therapeutics announced the appointment of Lisa Pitt, Pharm.D., M.S.J. as Senior Vice President of Regulatory Affairs and Shiguang Liu, M.D. to the company. These are key regulatory and clinical appointments disclosed by the company.

Why it matters — New regulatory and clinical leadership could strengthen Jasper Therapeutics' capabilities in advancing its programs.

Jasper Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference

GlobeNewsWire · 9 Sept 2026neutral

Jasper Therapeutics, Inc. (Nasdaq: JSPR), a clinical-stage biotechnology company developing therapies for immune-mediated diseases, announced that its management will participate at the H.C. Wainwright 28th Annual Global Investment Conference. The announcement was made on September 9, 2026, from the company's headquarters in Redwood City, California.

Why it matters — A JSPR watcher would care because management's participation at a major investment conference provides an opportunity for the company to engage with investors and increase visibility in the financial community.

Jasper Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

GlobeNewsWire · 14 Aug 2026positive

Jasper Therapeutics reported its second quarter 2026 financial results and provided a corporate update. The company noted that its acquisition of Kira Pharmaceuticals closed in July, creating a combined company with a portfolio of clinical stage assets focused on immunologically-driven disorders.

Why it matters — JSPR watchers would care because the completed Kira Pharmaceuticals acquisition meaningfully expands the company's clinical-stage pipeline in immunologically-driven disorders.

FAQ

Frequently asked questions about JSPR stock

What is the JSPR stock price forecast for 2026-2027?

The 2 Wall Street analysts covering Jasper Therapeutics, Inc. have a median 12-month price target of $20, with estimates ranging from $20 to $20. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is JSPR stock a buy right now?

Of the 2 analysts covering Jasper Therapeutics, Inc., 2 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Jasper Therapeutics, Inc. 42 out of 100 across roughly 4,600 US stocks as at 27 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank JSPR?

As at 27 Oct 2026, Jasper Therapeutics, Inc. ranks 42 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (88 of 100).

Will JSPR stock go up?

No one can know that. What the data says: the median 12-month target from 2 analysts implies +3612.0% from the last close, and Ticker Nerd's factor model ranks Jasper Therapeutics, Inc. 42 out of 100 as at 27 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the JSPR stock forecast for 2030?

No analyst covering Jasper Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for JSPR are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $20 to $20 over the next 12 months.

How has JSPR stock performed over the past year?

Jasper Therapeutics, Inc. returned -77.0% over the 12 months to 28 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Jasper Therapeutics, Inc. do?

Jasper Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies for mast cell-driven and immune-mediated diseases.

What is the latest news on JSPR?

The most recent item we track (GlobeNewsWire, 15 Oct 2026): "Jasper Therapeutics Announces Completion of Enrollment in First Cohort of Phase 2 Renal Basket Study Evaluating Vensobafusp Alfa (KP104) in IgA Nephropathy". Jasper Therapeutics announced completion of enrollment in the IgA nephropathy cohort of its Phase 2 renal basket study evaluating vensobafusp alfa (KP104). Initial Stage 1 data are expected by year-end 2026, and the company announced an FSGS expansion cohort, with first dosing anticipated in the first quarter of 2027.

Company

About Jasper Therapeutics, Inc.

Jasper Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies for mast cell-driven and immune-mediated diseases. The company’s lead program, briquilimab, is a monoclonal antibody designed to target the CD117 pathway and reduce mast cell activity, supporting research in conditions such as chronic spontaneous urticaria, chronic inducible urticaria, and asthma. Jasper Therapeutics also works on hematopoietic stem cell-based approaches, including conditioning regimens intended to support stem cell transplantation and ex vivo gene therapy. Its current business is centered on clinical development, translational research, and advancing therapeutic candidates for patients with serious inflammatory, immunological, and transplant-related disorders. Headquartered in Redwood City, California, Jasper Therapeutics operates in the biotechnology sector and focuses on programs that aim to address high unmet medical needs through targeted biological therapies.

CEO Mr. Jeetinder Singh Mahal M.B.A. · 22 employees · United States · https://jaspertx.com